Volume 21, Number 3—March 2015
Dispatch
Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA
Lisa Trieu
, Douglas C. Proops, and Shama D. Ahuja
, Douglas C. Proops, and Shama D. Ahuja
Table 2
Multidrug resistant tuberculosis contact investigation results at 2 sites, by HIV status and country of birth, New York, New York, USA*
| Site | US-born, no. (%) | Foreign-born, no. (%) | Unknown country of birth, no. (%) | Total, no. (%) | |
|---|---|---|---|---|---|
| Site A | |||||
| No. contacts | 87 | 6 | 12 | 105 | |
| HIV-positive | 68 (78) | 4 (67) | 12 (100) | 84 (80) | |
| Eligible for testing† | 56 (82) | 1 (25) | 12 (100) | 69 (82) | |
| Tested | 22 (39) | 1 (100) | 2 (17) | 25 (36) | |
| TST positive | 3 (14) | 0 (0) | 0 (0) | 3 (12) | |
| Initiated treatment | 24 (35) | 3 (75) | 2 (17) | 29 (35) | |
| Treated with moxifloxacin | 21 (88) | 3 (100) | 2 (100) | 26 (90) | |
| Completed treatment | 13 (62) | 2 (67) | 1 (50) | 16 (62) | |
| Treated with alternate regimen | 3 (13) | 0 (0) | 0 | 3 (10) | |
| Did not initiate treatment | 44 (65) | 1 (25) | 10 (83) | 55 (65) | |
| Lost to follow-up | 28 (64) | 1 (100) | 10 (100) | 39 (71) | |
| Refused evaluation or treatment | 12 (27) | 0 (0) | 0 | 12 (22) | |
| Died before testing or treatment | 1 (2) | 0 (0) | 0 | 1 (2) | |
| Physician decision to not treat | 3 (7) | 0 (0) | 0 | 3 (5) | |
| HIV-negative | 14 (16) | 2 (33) | 0 | 16 (15) | |
| Eligible for testing* | 11 (79) | 1 (50) | 0 | 12 (75) | |
| Tested | 3 (27) | 1 (100) | 0 | 4 (33) | |
| TST positive | 0 (0) | 1 (100) | 0 | 1 (25) | |
| HIV status unknown | 5 (6) | 0 (0) | 0 | 5 (5) | |
| Eligible for testing* | 3 (60) | 0 | 0 | 3 60) | |
| Tested | 0 | 0 | 0 | 0 | |
| TST positive |
0 |
0 |
0 |
0 |
|
| Site B | |||||
| No. contacts | 47 | 1 | 88 | 136 | |
| HIV-positive | 47 (100) | 1 (100) | 35 (40) | 83 (61) | |
| Eligible for testing* | 45 (96) | 0 | 31 (89) | 76 (92) | |
| Tested | 20 (44) | NA | 20 (65) | 40 (53) | |
| TST-positive | 3 (15) | 0 | 0 (0) | 3 (8) | |
| Initiated treatment | 16 (34) | 1 (100) | 14 (40) | 31(37) | |
| Treated with pyrazinamide/moxifloxacin | 12 (75) | 1 (100) | 11 (79) | 24 (77) | |
| Completed treatment | 9 (75) | 1 (100) | 4 (36) | 14 (58) | |
| Treated with alternate regimen | 4 (25) | 0 | 3 (21) | 7 (23) | |
| Did not initiate treatment | 31 (66) | 0 | 21 (60) | 52 (63) | |
| Lost to follow-up | 15 (48) | NA | 11 (52) | 26 (50) | |
| Refused evaluation or treatment | 2 (6) | NA | 1 (5) | 3 (6) | |
| Died before testing or treatment | 12 (39) | NA | 2 (10) | 14 (27) | |
| Physician decision to not treat | 2 (6) | NA | 7 (33) | 9 (17) | |
| HIV status unknown | 0 | 0 | 53 (60) | 53 (39) | |
| Eligible for testing* | NA | NA | 28 (53) | 28 (53) | |
| Tested | NA | NA | 25 (89) | 25 (89) | |
| TST positive | NA | NA | 0 (0) | 0 | |
*Site A was a facility that provided housing and harm-reduction services to a predominantly HIV-positive, homeless, and drug-using population. Site B was a long-term care facility housing HIV-positive, homeless persons. TST, tuberculin skin test.
†Any person who had a history of positive TST result was considered ineligible for testing.
Page created: February 20, 2015
Page updated: February 20, 2015
Page reviewed: February 20, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.